Workshop: IPTA-SPLIT: Cardiac liver disease
Friday September 19, 2025 from 11:05 to 12:05
MOA 5
Session Sponsored by:

Description
- Discuss the definition of congestive hepatopathy and cardiac liver disease as whole – including long-term complications and the importance of monitoring
- Review the benefits of liver biopsy in the management of congestive hepatopathy and its impact on the transplant discussion.
- Examine the risk associated with liver biopsy in this patient population and alternative ways to monitor complications of congestive hepatopathy – including the mixed review of liver biopsy pathology benefit
Lectures
  • Congestive hepatopathy: Risks, surveillance and management
    Dr. Chaowapong Jarasvaraparn, United States
  • Liver biopsy is key: The importance of a liver biopsy for disease management and long-term predictions
    Dr. Alyssa Kriegermeier, United States
  • Liver biopsy is too risky without reward: Alternative ways to monitor congestive hepatopathy and why liver biopsy is not needed
    Elizabeth Rand, United States
  • Pro liver biopsy response
    Dr. Alyssa Kriegermeier, United States
  • Con liver biopsy response
    Elizabeth Rand, United States
  • Questions from Audience
    Discussion Period, Germany

© 2025 IPTA 2025